HOWL on Nasdaq

Werewolf Therapeutics, Inc.

We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerHOWL on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inDE2
  • Business address303 Wyman Street, Suite 300, Waltham, Ma 024512
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINE and INDUCER molecules, are intended to activate selectively in the tumor microenvironment, or TME. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12), respectively, INDUKINE molecules for the treatment of multiple tumor types.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$60.7M in 2025+171% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$22.4M-$22.4M20202021: -$50.1M-$50.1M2021+124%2022: -$56.1M-$56.1M2022+12%2023: -$40.5M-$40.5M2023−28%2024: -$73.6M-$73.6M2024+82%2025: -$60.7M-$60.7M2025−18%
Net income45678-$60.8M in 2025+304% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$15.0M-$15.0M20202021: -$50.0M-$50.0M2021+232%2022: -$53.8M-$53.8M2022+8%2023: -$37.4M-$37.4M2023−31%2024: -$70.5M-$70.5M2024+89%2025: -$60.8M-$60.8M2025−14%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Collaboration revenue$0$1.9M
Research and development$44.8M$56.4M
General and administrative$15.8M$19.0M
Total operating expenses$60.7M$75.5M
Operating loss-$60.7M-$73.6M
Interest income$3.1M$6.7M
Interest expense-$5.3M-$4.7M
Loss on extinguishment of debt$0-$553.0K
Other income, net$2.0M$1.6M
Total other (expense) income-$145.0K$3.1M
Net loss-$60.8M-$70.5M
Net loss per common share, basic (in usd per share)-$1.32-$1.63
Net loss per common share, diluted (in usd per share)-$1.33-$1.63
Weighted average common shares outstanding, basic (in shares)46.0M shares43.3M shares
Weighted average common shares outstanding, diluted (in shares)46.8M shares43.9M shares

Compare Werewolf Therapeutics, Inc. with another company

Leadership

Who has led Werewolf Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Timothy W. Trost2021–now

Chief operating officer

  1. Reid Leonard2021–2023
2025
Board members and other officers (17)

Filings

369 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 124 insider forms, 35 large holders, 143 other. The latest 20:

  1. Sep 22, 2026S-4 EDGAR
  2. Sep 21, 2026SCHEDULE 13G EDGAR
  3. Aug 21, 2026425 EDGAR
  4. Aug 21, 20268-K EDGAR
  5. Aug 20, 20268-K EDGAR
  6. Jul 31, 202610-Q EDGAR
  7. Jul 31, 20268-K EDGAR
  8. Jul 8, 20264 EDGAR
  9. Jul 6, 2026144 EDGAR
  10. Jul 6, 2026144 EDGAR
  11. Jul 6, 2026144 EDGAR
  12. Jul 6, 2026144 EDGAR
  13. Jul 6, 2026144 EDGAR
  14. Jul 6, 2026144 EDGAR
  15. Jul 2, 2026SCHEDULE 13D/A EDGAR
  16. Jun 29, 2026144 EDGAR
  17. Jun 29, 2026144 EDGAR
  18. Jun 29, 2026144 EDGAR
  19. Jun 29, 2026144 EDGAR
  20. Jun 29, 2026144 EDGAR

The 369 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

161 open-market trades by officers, directors and large owners since October 2021: 4 buys and 157 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 7, 2026EVNIN LUKEDirectorSale107,429$0.31$33.3KForm 4
Jul 6, 2026EVNIN LUKEDirectorSale35,770$0.32$11.4KForm 4
Jun 29, 2026EVNIN LUKEDirectorSale157,084$0.30$47.1KForm 4
Jun 17, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale416,911$0.35$145.9KForm 4
Jun 16, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale149,625$0.37$55.4KForm 4
Jun 15, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale128,770$0.39$50.2KForm 4
Jun 12, 2026RA CAPITAL MANAGEMENT, L.P.10% ownerSale170,441$0.40$68.2KForm 4
Jun 11, 2026Kolchinsky Peter10% ownerSale262,503$0.38$99.8KForm 4
Jun 10, 2026Kolchinsky Peter10% ownerSale45,923$0.37$17.0KForm 4
Jun 9, 2026Kolchinsky Peter10% ownerSale369,800$0.37$136.8KForm 4
Jun 9, 2026EVNIN LUKEDirectorSale76,928$0.37$28.5KForm 4
Jun 8, 2026EVNIN LUKEDirectorSale60,547$0.40$24.2KForm 4
Jun 5, 2026EVNIN LUKEDirectorSale24,946$0.40$10.0KForm 4
Jun 4, 2026EVNIN LUKEDirectorSale20,072$0.44$8.8KForm 4
Jun 3, 2026EVNIN LUKEDirectorSale29,749$0.42$12.5KForm 4
Jun 2, 2026EVNIN LUKEDirectorSale29,595$0.45$13.3KForm 4
Jun 1, 2026EVNIN LUKEDirectorSale80,459$0.47$37.8KForm 4
May 29, 2026EVNIN LUKEDirectorSale32,556$0.45$14.7KForm 4
May 28, 2026EVNIN LUKEDirectorSale27,698$0.46$12.7KForm 4
May 27, 2026EVNIN LUKEDirectorSale80,852$0.48$38.8KForm 4

All 161 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.2,387,744$859.3K0.0%−4,293,563
Balyasny Asset Management L.P.1,790,089$644.3K0.0%New
Vanguard Capital Management LLC1,217,976$438.5K0.0%No change
Renaissance Technologies LLC674,632$242.8K0.0%+158,414
Lynx1 Capital Management LP657,786$236.7K0.0%No change
Sphera Funds Management Ltd.626,810$225.6K0.0%No change
DC Funds, LP589,102$212.0K16.9%No change
Verdad Advisers, LP348,709$125.5K0.1%+318,949
Geode Capital Management, LLC335,815$120.9K0.0%−53,672
Bank Of America Corp /de/311,502$111.8K0.0%+46,919
XTX Topco Ltd271,478$97.7K0.0%+220,549
Jane Street Group, LLC251,837$90.6K0.0%+169,001
UBS Group AG215,838$77.7K0.0%+148,981
Vanguard Fiduciary Trust Co157,726$56.8K0.0%No change
State Street Corp119,168$42.9K0.0%No change
Squarepoint Ops LLC103,242$37.2K0.0%New
BlackRock, Inc.101,573$36.6K0.0%−35
Rangeley Capital, LLC100,000$36.0K0.0%New
Northern Trust Corp86,851$31.3K0.0%No change
Alyeska Investment Group, L.P.86,554$31.2K0.0%No change
Mpm Bioimpact LLC80,142$28.9K0.0%−1,128,668
Millennium Management LLC62,055$22.3K0.0%−69,995
Two Sigma Investments, LP27,300$9.8K0.0%New
StoneX Group Inc.20,000$9.0K0.0%New
Goldman Sachs Group Inc20,023$7.2K0.0%−18,243

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37